Alterations in homologous recombination repair genes in prostate

Tumor immune microenvironment of primary prostate cancer with and without germline mutations in homologous recombination repair genes

RB1 loss overrides PARP inhibitor sensitivity driven by RNASEH2B loss in prostate cancer

Full article: Exploiting defects in homologous recombination repair for metastatic, castration-resistant prostate cancer

PARP Inhibition in Prostate Cancer With Homologous Recombination Repair Alterations

Prostate cancer and PARP inhibitors: progress and challenges, Journal of Hematology & Oncology

Prevalence of DNA repair gene mutations in localized prostate cancer according to clinical and pathologic features: association of Gleason score and tumor stage

Targeting DNA Repair Defects for Precision Medicine in Prostate Cancer

Targeting MALAT1 Augments Sensitivity to PARP Inhibition by Impairing Homologous Recombination in Prostate Cancer

Improving Patient Access to Homologous Recombination Deficiency Testing for Precision Oncology

Genetic testing for homologous recombination repair (HRR) in metastatic castration-resistant prostate cancer (mCRPC): challenges and solutions

ASCO GU 2020: Contemporary Clinical Impact of Genetic and Genomic Testing in Prostate Cancer

PARP inhibitor applicability

Alterations in homologous recombination repair genes in prostate cancer brain metastases

Prognostic and therapeutic implications of DNA repair gene mutations in advanced prostate cancer.

Targeting homologous recombination deficiency (HRD) in cancer research - SOPHiA GENETICS